She cannot do that. Conflict of interest and if LP sanctions this, theft of employee services---if she is, indeed, an employee.
No, Keil is un-necessary and a waste of valuable resources. Why hire an investment banker? Rather, engage an investment bank as, if and when needed. Les and Linda have loads of experience in M&A, JVs, partnerships, etc. LG, as GC, can easily vet any interest and valuation. LG has specifically told me that they have a valuation in mind. He did not say what it was but they sure don't need a Johnny come lately to tell them what they already know in spades.
At this stage in the game, the only valuation that the market at large is interested in is RESULTS PERIOD.
If the results are undeniable, trust me, there will be interest and derived value. Interested parties will be there. No need for a hired investment banker employee either now or in the future. This is just as useless and an abject waste of resources as was DI's hire. I have seen no value that he puts forth. He is a puppet whose strings are manipulated by LG.
I am not interested, at this point, in any blinded update. If we get it, it is a signal that we won't see TLD for some time. Such an update would only serve as a palliative. All that matters is TLD and undeniable results. I would hope that TLD is revealed before the ASM. I don't believe any investors would be happy to hear again "ginormous", "soon", "stay tuned", "we are nearly there", "just a bit more to tie up loose ends", etc. Then we are easily looking at ASCO 2020 at the earliest. It would also signal that there is a hold up by RAs in "approving" the SAP. LP made a statement, as I recall, of obtaining RA approval on the SAP. If that is so, then, contrary to DI statements in telecon conversations, the RAs must respond either with comments, rejection, or approval. Then, if as LP has indicated, "approval" of the SAP is required, for the jurisdictions applied for, then NWBO is handcuffed and cannot go forward with this SAP until "approved".
I cannot believe that NWBO has not been in an iterative process, especially with orphan status, with the RAs especially the FDA. They are working with regulatory consultants. If they have been involved in such an iterative process, approval/buy-in, cannot be very far off unless they have hit snags in this process which I personally believe is rather doubtful. Accordingly, I think they are in the home stretch waiting for final approvals which could come at any time.
IMHO, concerns loom IF we get an update on BLINDED results. No need for that if TLD is relatively near around the corner. And....if we don't get TLD before the ASM then I think the Series B warrants expiring in April are under serious threat. A rather ominous prospect. As they say, "stay tuned" JMHO.
